C4 Therapeutics (CCCC) Non Operating Income (2019 - 2026)

C4 Therapeutics has reported Non Operating Income for 8 years, with the latest figure at $2.7 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income fell 6.54% year-over-year to $2.7 million; the trailing twelve-month figure through Mar 2026 stood at $10.2 million (down 24.23% YoY), and the FY2025 full-year result was $10.3 million, down 28.28% from the prior year.
• Non Operating Income for Q1 2026 stood at $2.7 million, down from $2.8 million in the prior quarter.
• The five-year high for Non Operating Income was $3.9 million in Q1 2024, with the low at -$251000.0 in Q1 2022.
• Average Non Operating Income over 5 years is $2.2 million, with a median of $2.5 million recorded in 2025.
• Year-over-year, Non Operating Income soared 5978.57% in 2023 and sank 37.23% in 2025.
• Tracing CCCC's Non Operating Income over 5 years: stood at $1.1 million in 2022, then soared by 166.25% to $2.9 million in 2023, then rose by 10.75% to $3.3 million in 2024, then declined by 14.91% to $2.8 million in 2025, then retreated by 4.46% to $2.7 million in 2026.
• The last three Non Operating Income figures came in at $2.7 million (Q1 2026), $2.8 million (Q4 2025), and $2.2 million (Q3 2025), per Business Quant data.

Peer Comparison